Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 2/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263186 | 0.89 | TEK (0.40) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5261380 | 0.86 | MAPT (0.50) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5261912 | 0.86 | AKT1 (0.47) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5265009 | 0.83 | AKT1 (0.46) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5261592 | 0.81 | AKT1 (0.46) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5260973 | 0.81 | AKT1 (0.43) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5263539 | 0.80 | AKT1 (0.42) | TEKAKT1AKT2PTGS1PTGS2 | |
| SCHEMBL5265447 | 0.80 | AKT1 (0.54) | AKT1AKT2PTGS1PTGS2MAPT | |
| SCHEMBL5261861 | 0.76 | AKT1 (0.45) | AKT1AKT2PTGS1PTGS2MAPT | |
| SCHEMBL5264520 | 0.76 | AKT1 (0.45) | AKT1AKT2PTGS1PTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | TEK 3673/4885AKT1 3579/4885AKT2 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.